SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-113231"
 

Sökning: id:"swepub:oai:DiVA.org:oru-113231" > Clinical utility of...

  • Mondello, StefaniaUniversity of Florida, Gainesville, Florida, United States; Banyan Biomarkers, Inc, Alachua, Florida, United States (författare)

Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury

  • Artikel/kapitelEngelska2012

Förlag, utgivningsår, omfång ...

  • Wolters Kluwer,2012
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-113231
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-113231URI
  • https://doi.org/10.1227/NEU.0b013e318236a809DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies:United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USAUnited States Department of DefenseUniversity of Florida
  • Background: Brain damage markers released in cerebrospinal fluid (CSF) and blood may provide valuable information about diagnosis and outcome prediction after traumatic brain injury (TBI).Objective: To examine the concentrations of ubiquitin C-terminal hydrolase-L1 (UCH-L1), a novel brain injury biomarker, in CSF and serum of severe TBI patients and their association with clinical characteristics and outcome.Methods: This case-control study enrolled 95 severe TBI subjects (Glasgow Coma Scale [GCS] score, 8). Using sensitive UCH-L1 sandwich ELISA, we studied the temporal profile of CSF and serum UCH-L1 levels over 7 days for severe TBI patients.Results: Comparison of serum and CSF levels of UCH-L1 in TBI patients and control subjects shows a robust and significant elevation of UCH-L1 in the acute phase and over the 7-day study period. Serum and CSF UCH-L1 receiver-operating characteristic curves further confirm strong specificity and selectivity for diagnosing severe TBI vs controls, with area under the curve values in serum and CSF statistically significant at all time points up to 24 hours (P < .001). The first 12-hour levels of both serum and CSF UCH-L1 in patients with GCS score of 3 to 5 were also significantly higher than those with GCS score of 6 to 8. Furthermore, UCH-L1 levels in CSF and serum appear to distinguish severe TBI survivors from nonsurvivors within the study, with nonsurvivors having significantly higher and more persistent levels of serum and CSF UCH-L1. Cumulative serum UCH-L1 levels > 5.22 ng/mL predicted death (odds ratio, 4.8).Conclusion: Serum levels of UCH-L1 appear to have potential clinical utility in diagnosing TBI, including correlating to injury severity and survival outcome.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Linnet, AkinyiBanyan Biomarkers, Inc, Alachua, Florida, United States (författare)
  • Büki, Andras,1966-University of Pecs, Pecs, Hungary(Swepub:oru)asbi (författare)
  • Robicsek, StevenUniversity of Florida, Gainesville, Florida, United States (författare)
  • Gabrielli, AndreaUniversity of Florida, Gainesville, Florida, United States (författare)
  • Tepas, JosephUniversity of Florida, Jacksonville, Florida, United States (författare)
  • Papa, LindaOrlando Regional Medical Center, Emergency Medicine, Orlando, Florida, United States (författare)
  • Brophy, Gretchen M.Virginia Commonwealth University, Pharmacotherapy & Outcomes Sciences and Neurosurgery, Richmond, Virginia, United States (författare)
  • Tortella, FrankWalter Reed Army Institute of Research, Silver Spring, Maryland, United States (författare)
  • Hayes, Ronald L.University of Florida, Gainesville, Florida, USA; Banyan Biomarkers, Inc, Alachua, Florida, United States (författare)
  • Wang, Kevin K.Banyan Biomarkers, Inc, Alachua, Florida, USA; University of Florida, Gainesville, Florida, United States (författare)
  • University of Florida, Gainesville, Florida, United States; Banyan Biomarkers, Inc, Alachua, Florida, United StatesBanyan Biomarkers, Inc, Alachua, Florida, United States (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Neurosurgery: Wolters Kluwer70:3, s. 666-6750148-396X1524-4040

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy